Seminars in Pediatric Surgery
Volume 17, Issue 2 , Pages 123-130 , May 2008

Outcomes following liver transplantation

References 

  1. HRSA OPatn. Final rule with comment period. Fed Reg. 1998;63:16296–16338
  2. McDiarmid SV, Goodrich NP, Harper AM, et al. Liver transplantation for status 1: the consequences of good intentions. Liver Transplant. 2007;13(5):699–707
  3. Shneider BL, Neimark E, Frankenberg T, et al. Critical analysis of the pediatric end-stage liver disease scoring system: a single center experience. Liver Transplant. 2005;11(7):788–795
  4. Shneider BL, Suchy FJ, Emre S. National and regional analysis of exceptions to the Pediatric End-Stage Liver Disease scoring system (2003-2004). Liver Transplant. 2006;12(1):40–45
  5. Olthoff KM, Brown RS, Delmonico FL, et al. Summary report of a national conference: evolving concepts in liver allocation in the MELD and PELD era. December 8, 2003, Washington, DC Liver Transplant. 2004;10(10):A6–A22(suppl 2)
  6. Merion RM, Schaubel DE, Dykstra DM, et al. The survival benefit of liver transplantation. Am J Transplant. 2005;5(2):307–313
  7. Taylor RM, Cheeseman P, Rela M, et al. The predictive value of the PELD model after Liver Transplantation in children. (Abstract) J Pediatr Gastroenterol Nutr. 2002;34:435
  8. Bourdeaux C, Tri TT, Gras J, et al. PELD score and posttransplant outcome in pediatric liver transplantation: a retrospective study of 100 recipients. Transplantation. 2005;79(9):1273–1276
  9. Asthana S, McClean P, Stringer MD. Does the pediatric end-stage liver disease score or hepatic artery resistance index predict outcome after liver transplantation for biliary atresia?. Pediatr Surg Int. 2006;22(9):697–700
  10. Barshes NR, Lee TC, Udell IW, et al. The pediatric end-stage liver disease (PELD) model as a predictor of survival benefit and posttransplant survival in pediatric liver transplant recipients. Liver Transplant. 2006;12(3):475–480
  11. Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant. 2006;6(4):783–790
  12. Reding R, de Goyet Jde V, Delbeke I, et al. Pediatric liver transplantation with cadaveric or living related donors: comparative results in 90 elective recipients of primary grafts. J Pediatr. 1999;134(3):280–286
  13. Sieders E, Peeters PM, TenVergert EM, et al. Analysis of survival and morbidity after pediatric liver transplantation with full-size and technical-variant grafts. Transplantation. 1999;68(4):540–545
  14. Roberts JP, Hulbert-Shearon TE, Merion RM, et al. Influence of graft type on outcomes after pediatric liver transplantation. Am J Transplant. 2004;4(3):373–377
  15. Diamond IR, Fecteau A, Millis JM, et al. Impact of graft type on outcome in pediatric liver transplantation: a report From Studies of Pediatric Liver Transplantation (SPLIT). Ann Surg. 2007;246(2):301–310
  16. Ryckman FC, Flake AW, Fisher RA, et al. Segmental orthotopic hepatic transplantation as a means to improve patient survival and diminish waiting-list mortality. J Pediatr Surg. 1991;26(4):422–427discussion 427-8.
  17. Ghobrial RM, Farmer DG, Amersi F, et al. Advances in pediatric liver and intestinal transplantation. Am J Surg. 2000;180(5):328–334
  18. Cacciarelli TV, Esquivel CO, Moore DH, et al. Factors affecting survival after orthotopic liver transplantation in infants. Transplantation. 1997;64(2):242–248
  19. Woodle ES, Millis JM, So SK, et al. Liver transplantation in the first three months of life. Transplantation. 1998;66(5):606–609
  20. Tiao GM, Alonso M, Bezerra J, et al. Liver transplantation in children younger than 1 year: the Cincinnati experience. J Pediatr Surg. 2005;40(1):268–273
  21. Farmer DG, Venick RS, McDiarmid SV, et al. Predictors of outcomes after pediatric liver transplantation: an analysis of more than 800 cases performed at a single institution. J Am Coll Surg. 2007;204(5):904–914discussion 914-6.
  22. Rhee C, Narsinh K, Venick RS, et al. Predictors of clinical outcome in children undergoing orthotopic liver transplantation for acute and chronic liver disease. Liver Transplant. 2006;12(9):1347–1356
  23. Soltys KA, Mazariegos GV, Squires RH, et al. Late graft loss or death in pediatric liver transplantation: an analysis of the SPLIT database. Am J Transplant. 2007;7(9):2165–2171
  24. Bucuvalas JC, Campbell KM, Cole CR, et al. Outcomes after liver transplantation: keep the end in mind. J Pediatr Gastroenterol Nutr. 2006;43(1):S41–S48
  25. McDiarmid SV, Merion RM, Dykstra DM, et al. Selection of pediatric candidates under the PELD system. Liver Transpl. 2004;10(10):S23–S30(suppl 2)
  26. McDiarmid SV. Risk factors and outcomes after pediatric liver transplantation. Liver Transplant Surg. 1996;2(5):44–56(suppl 1)
  27. Close P, Burkey E, Kazak A, et al. A prospective, controlled evaluation of home chemotherapy for children with cancer. Pediatrics. 1995;95(6):896–900
  28. Britto MT, Kotagal UR, Hornung RW, et al. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest. 2002;121(1):64–72
  29. Pyne JM, Bullock D, Kaplan RM, et al. Health-related quality-of-life measure enhances acute treatment response prediction in depressed inpatients. J Clin Psychiatry. 2001;62(4):261–268
  30. Wolpert HA, Anderson BJ. Management of diabetes: are doctors framing the benefits from the wrong perspective?. Br Med J. 2001;323(7319):994–996
  31. Bucuvalas JC, Britto M, Krug S, et al. Health-related quality of life in pediatric liver transplant recipients: a single-center study. Liver Transplant. 2003;9(1):62–71
  32. Cole CR, Bucuvalas JC, Hornung RW, et al. Impact of liver transplantation on HRQOL in children less than 5 years old. Pediatr Transplant. 2004;8(3):222–227
  33. Alonso EM, Neighbors K, Mattson C, et al. Functional outcomes of pediatric liver transplantation. J Pediatr Gastroenterol Nutr. 2003;37(2):155–160
  34. Fine RN, Alonso EM, Fischel JE, et al. Pediatric transplantation of the kidney, liver and heart: summary report. Pediatr Transplant. 2004;8(1):75–86
  35. Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation. 2001;72(12):1934–1939
  36. Gonwa TA. Hypertension and renal dysfunction in long-term liver transplant recipients. Liver Transplant. 2001;7(11):S22–S26(suppl 1)
  37. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349(10):931–940
  38. Campbell KM, Yazigi N, Ryckman FC, et al. High prevalence of renal dysfunction in long-term survivors after pediatric liver transplantation. J Pediatr. 2006;148(4):475–480
  39. Berg UB, Ericzon BG, Nemeth A. Renal function before and long after liver transplantation in children. Transplantation. 2001;72(4):631–637
  40. Herzog D, Martin S, Turpin S, et al. Normal glomerular filtration rate in long-term follow-up of children after orthotopic liver transplantation. Transplantation. 2006;81(5):672–677
  41. Aw MM, Samaroo B, Baker AJ, et al. Calcineurin-inhibitor related nephrotoxicity- reversibility in paediatric liver transplant recipients. Transplantation. 2001;72(4):746–749
  42. Pageaux GP, Rostaing L, Calmus Y, et al. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transplant. 2006;12(12):1755–1760
  43. Everhart JE, Lombardero M, Lake JR, et al. Weight change and obesity after liver transplantation: incidence and risk factors. Liver Transplant Surg. 1998;4(4):285–296
  44. Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology. 2002;35(1):105–109
  45. Varo E, Padin E, Otero E, et al. Cardiovascular risk factors in liver allograft recipients: relationship with immunosuppressive therapy. Transplant Proc. 2002;34(5):1553–1554
  46. Textor SC, Taler SJ, Canzanello VJ, et al. Posttransplantation hypertension related to calcineurin inhibitors. Liver Transplant. 2000;6(5):521–530
  47. Tiao GM, Bobey N, Allen S, et al. The current management of hepatoblastoma: a combination of chemotherapy, conventional resection, and liver transplantation. J Pediatr. 2005;146(2):204–211
  48. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl. 1998;147–158
  49. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf. 2000;23(2):101–113
  50. Guthery SL, Heubi JE, Bucuvalas JC, et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation. 2003;75(7):987–993
  51. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood. 2006;107(8):3053–3057
  52. Gross TG, Bucuvalas JC, Park JR, et al. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol. 2005;23(27):6481–6488
  53. Lee TC, Savoldo B, Rooney CM, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant. 2005;5(9):2222–2228
  54. Yang J, Tao Q, Flinn IW, et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood. 2000;96(13):4055–4063
  55. Penn I. Malignant melanoma in organ allograft recipients. Transplantation. 1996;61(2):274–278
  56. Lurie S, Shemesh E, Sheiner PA, et al. Non-adherence in pediatric liver transplant recipients: an assessment of risk factors and natural history. Pediatr Transplant. 2000;4(3):200–206
  57. Penkower L, Dew MA, Ellis D, et al. Psychological distress and adherence to the medical regimen among adolescent renal transplant recipients. Am J Transplant. 2003;3(11):1418–1425
  58. Fredericks EM, Lopez MJ, Magee JC, et al. Psychological functioning, nonadherence and health outcomes after pediatric liver transplantation. Am J Transplant. 2007;7(8):1974–1983
  59. Shemesh E, Shneider BL, Savitzky JK, et al. Medication adherence in pediatric and adolescent liver transplant recipients. Pediatrics. 2004;113(4):825–832
  60. Bucuvalas JC, Ryckman FC, Arya G, et al. A novel approach to managing variation: outpatient therapeutic monitoring of calcineurin inhibitor blood levels in liver transplant recipients. J Pediatr. 2005;146(6):744–750
  61. Horslen S, Barr ML, Christensen LL, et al. Pediatric transplantation in the United States, 1996-2005. Am J Transplant. 2007;7(5):1339–1358

PII: S1055-8586(08)00009-7

doi: 10.1053/j.sempedsurg.2008.02.008

Seminars in Pediatric Surgery
Volume 17, Issue 2 , Pages 123-130 , May 2008

Article Tools

* Image Usage & Resolution